Article ID Journal Published Year Pages File Type
8237156 International Journal of Radiation Oncology*Biology*Physics 2008 8 Pages PDF
Abstract
Capecitabine at 725 mg/m2 orally twice daily, oxaliplatin 50 mg/m2/wk, and RT at 50.4 Gy is an effective neoadjuvant combination for Stage II and III rectal cancer and results in a greater rate of complete pathologic responses than historically shown in fluoropyrimidine plus RT controls.
Keywords
Related Topics
Physical Sciences and Engineering Physics and Astronomy Radiation
Preview
Phase II Study of Weekly Intravenous Oxaliplatin Combined With Oral Daily Capecitabine and Radiotherapy With Biologic Correlates in Neoadjuvant Treatment of Rectal Adenocarcinoma
Authors
, , , , , , , , , , , ,